(2 mg + 0.05 mg + 4 mg)/ml, liquid for the skin
Prednisolone + Estradiol benzoate + Salicylic acid
Alpicort E is a liquid for the skin, containing prednisolone, female sex hormones, and salicylic acid for use on the scalp.
Indications: in various forms of alopecia, especially androgen-dependent alopecia.
Before starting treatment with Alpicort E, you should discuss it with your doctor or pharmacist.
Alpicort E may be used only externally on the scalp due to its isopropyl alcohol content.
When treating for more than 2-3 weeks, due to the estrogen content in the liquid, special precautions should be taken:
Protect your eyes and mucous membranes from contact with the preparation.
If the patient experiences blurred vision or other vision disturbances, they should contact their doctor.
Alpicort E may enhance the effects of other topically applied active substances due to its composition.
You should inform your doctor or pharmacist about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take.
Pregnancy
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before using this medicine. Alpicort E should not be used during pregnancy due to its salicylic acid content, except when used on small areas (less than 5 cm²).
Alpicort E should not be used due to its estrogen content.
If the patient becomes pregnant during treatment, Alpicort E treatment should be stopped immediately. However, previous studies have not shown any effect on subsequent fertility due to exposure to estrogen. During long-term treatment with glucocorticoids, a component of Alpicort E, during pregnancy, growth disturbances and damage to the unborn child cannot be excluded.
Breastfeeding
The doctor should consider that prednisolone passes into breast milk during breastfeeding.
The doctor will carefully assess whether it is necessary to use Alpicort E during breastfeeding. If long-term treatment is necessary, breastfeeding should be stopped.
During breastfeeding, estrogens may change the amount and composition of human milk. Small amounts of estrogens or their metabolites may pass into the milk of breastfeeding women and affect the child. Glucocorticoids also pass into human milk. Therefore, during treatment with Alpicort E, breastfeeding should not be done, or treatment with Alpicort E should only be started after the end of the breastfeeding period.
Alpicort E does not affect the ability to drive vehicles or operate machinery.
The medicine contains 50 mg of propylene glycol in 1 ml of liquid (approximately equivalent to 180 mg of propylene glycol in a single application). Propylene glycol may cause skin irritation.
This medicine should always be used according to the doctor's recommendations. In case of doubts, you should consult a doctor or pharmacist.
Alpicort E should be used according to the doctor's recommendations and the instructions in this leaflet. In case of doubts, you should contact your doctor again.
Alpicort E is a liquid for use on the skin.
If the doctor does not recommend otherwise, Alpicort E should be used once a day, preferably in the evening.
Once the inflammatory symptoms have subsided, it is sufficient to use 2 to 3 times a week.
During each use, proceed as follows:
The treatment duration for small areas should not be longer than 2-3 weeks due to the presence of prednisolone in the liquid. Clinical experience includes a treatment period of up to 6 months.
No studies have been conducted on the duration of action after discontinuation of the medicine.
In case of using a higher dose than recommended, you should immediately consult a doctor or pharmacist.
You should not take a double dose to make up for a missed dose.
You should continue treatment by taking the next scheduled dose at the usual time.
You should discuss further action with your doctor, as the effectiveness of the treatment may be compromised.
In case of any further doubts about using this medicine, you should consult a doctor or pharmacist.
Like all medicines, Alpicort E can cause side effects, although not everybody gets them.
Rarely(may occur in less than 1 in 1,000 people): skin hypersensitivity (allergic contact dermatitis).
Very rarely(may occur in less than 1 in 10,000 people): as with the use of any corticosteroid preparations, long-term use may lead to skin changes (skin thinning, widening of small blood vessels, formation of striae, steroid acne, perioral dermatitis, excessive body hair).
Unknown(frequency cannot be estimated from the available data): blurred vision
Additionally, short-term skin irritations (e.g., burning, redness) are possible.
During long-term use in high doses or on large areas, as well as in cases of use not in accordance with the intended use, systemic corticosteroid effects are possible.
If you experience any side effects, including any side effects not listed in this leaflet, you should inform your doctor or pharmacist. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
website: https://smz.ezdrowie.gov.pl
By reporting side effects, you can help gather more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
Do not store above 30°C. Store in the original packaging to protect from light.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the specified month.
Medicines should not be disposed of via wastewater or household waste containers. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Alpicort E is a clear, colorless liquid. The packaging contains a glass bottle (type III hydrolytic class) with an applicator and a polypropylene closure containing 100 ml of the medicine and a leaflet.
For more detailed information, you should contact the marketing authorization holder or the parallel importer.
Dr. August Wolff GmbH & Co. KG Arzneimittel
Sudbrackstraße 56
33611 Bielefeld
Germany
Dr. August Wolff GmbH & Co. KG Arzneimittel
Sudbrackstraße 56
33611 Bielefeld
Germany
Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Delfarma Sp. z o.o.
ul. Św. Teresy od Dzieciątka Jezus 111
91-222 Łódź
Authorization number in Bulgaria, the country of export: 20011278
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.